BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20887125)

  • 1. Acromegaly: a review of current medical therapy and new drugs on the horizon.
    Fleseriu M; Delashaw JB; Cook DM
    Neurosurg Focus; 2010 Oct; 29(4):E15. PubMed ID: 20887125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
    Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
    Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
    Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
    J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
    Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
    Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
    Lissett CA; Peacey SR; Laing I; Tetlow L; Davis JR; Shalet SM
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):653-7. PubMed ID: 10197082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of stereotactic radiosurgery in the multimodal management of growth hormone-secreting pituitary adenomas.
    Stapleton CJ; Liu CY; Weiss MH
    Neurosurg Focus; 2010 Oct; 29(4):E11. PubMed ID: 20887121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
    Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
    Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent results of secondary transnasal surgery for residual or recurring acromegaly.
    Abe T; Lüdecke DK
    Neurosurgery; 1998 May; 42(5):1013-21; discussion 1021-2. PubMed ID: 9588545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term primary medical therapy with somatostatin analogs in acromegaly.
    Su DH; Liao KM; Chen HW; Chang TC
    J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].
    Jaquet P; Cortet-Rudelli Ch; Sassolas G; Morange-Ramos I; Chanson P; Brue T; Andrieu JM; Beckers A; Bertherat J; Borson-Chazot F; Brassier G; Caron P; Cogne M; Cottier JP; Delemer B; Dufour H; Enjalbert A; Figarella-Branger D; Gaillard R; Gueydan M; Jan M; Kuhn JM; Raingeard I; Regis J; Roger P; Rohmer V; Sadoul JL; Saveanu A; Tabarin A; Travers N; Trouillas J;
    Ann Endocrinol (Paris); 2003 Dec; 64(6):434-41. PubMed ID: 15067248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future directions of pharmacological therapy for acromegaly.
    Mercado M; Espinosa E; Ramírez C
    Minerva Endocrinol; 2016 Sep; 41(3):351-65. PubMed ID: 26485036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
    Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
    Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scalp hair loss caused by octreotide in a patient with acromegaly: a case report.
    Nakauchi Y; Kumon Y; Yamasaki H; Tahara K; Kurisaka M; Hashimoto K
    Endocr J; 1995 Jun; 42(3):385-9. PubMed ID: 7670568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
    Losa M; Garbin E; Pedone E; Mortini P
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.